Asthma Medication Formoterol Shows Promise For Treating Fatty Liver Disease

MUSC researchers are tackling MASH, aliases metabolic dysfunction-associated steatohepatitis, a liver illness affecting hundreds of millions worldwide. It is besides a starring origin of liver transplantation, yet curen options stay limited. 

A new paper published successful Nature partner diary (npj) Metabolic Health and Disease suggests that a wide utilized asthma medication, formoterol, could perchance connection a different therapeutic pathway altogether. Formoterol is simply a beta-2 adrenergic receptor agonist that has been prescribed for decades to unfastened airways successful conditions for illustration asthma and chronic obstructive pulmonary disease.

The activity began successful an different way, during nan people of kidney research. Researchers primitively tested formoterol successful rodent models of kidney wounded to find if nan supplier could amended nan harm associated pinch diabetes. During those experiments, which were successful and published successful nan American Journal of Physiology, Renal Physiology successful 2024, they noticed thing they hadn't anticipated: The mice receiving nan supplier besides appeared to person little liver fat.

"Kind of unexpectedly, we recovered that nan liver harm besides reversed," said Joshua Lipschutz, M.D., Division head of Nephrology and nan Arthur Williams Endowed Chair successful Nephrology. He is besides nan writer of nan study, conducted successful collaboration pinch Jessica Hartman, Ph.D., and Don Rockey, M.D., astatine MUSC. Brennan Winkler, a Ph.D. student from nan Lipschutz Lab, and Kristina Stayer, a Ph.D. student from nan Hartman Lab, were co-first authors.

That astonishment uncovering prompted a 2nd statement of investigation focused specifically connected nan liver and whether nan aforesaid beta-2 pathway could power metabolic illness crossed aggregate organs.

What nan study found 

To trial that question, nan squad utilized a high-fat fare rodent exemplary designed to mimic MASH. In nan follow-up study, curen pinch formoterol was associated pinch reversal of nan fatty liver.

"This really reversed nan pathology connected aggregate different levels," said Lipschutz. 

The study besides explored underlying pathways that whitethorn thief to explicate these changes. They recovered signs that nan supplier whitethorn power really cells nutrient and usage energy.

"It looked for illustration formoterol was rescuing nan wounded by expanding mitochondrial biogenesis," he explained. "It benignant of revs up nan mitochondria truthful they activity better."

To complement nan findings, nan squad conducted a retrospective study of patients who were already prescribed beta-2 agonists for respiratory conditions. In this real-world data, usage of nan narcotics was associated pinch importantly little rates of respective superior liver-related outcomes, including cirrhosis and all-cause mortality.

Why this matters for MASH treatment

MASH is nan progressive shape of fatty liver and represents nan shape astatine which fat accumulation originates to thrust ongoing liver injury. Over time, this tin lead to fibrosis, cirrhosis, liver nonaccomplishment and yet nan request for transplantation. Its prevalence is rising globally, on pinch increases successful obesity and Type 2 diabetes, making MASH 1 of nan astir urgent liver diseases successful position of a semipermanent nationalist wellness burden.

"At nan clip we started nan study, location were nary narcotics approved to dainty MASH," said Lipschutz.

There are now 2 approved therapies, resmetirom and semaglutide, which tin amended liver markers but stay only moderately effective and person broadside effects.

"All nan existent narcotics for diabetic nephropathy only slow progression, but they don't reverse nan damage. This supplier really reversed nan harm astatine nan histologic, ultrastructural and functional levels," noted Lipschutz.

Formoterol is already an established medication, utilized for years successful asthma and chronic obstructive pulmonary disease, pinch a well-established information profile. If its metabolic effects are confirmed successful humans, this existing way grounds would importantly velocity up nan way toward further improvement and testing.

"If you tin repurpose thing that's approved and already being utilized safely, that's benignant of our dream arsenic physician-scientists," he said.

Why nan first proceedings targets kidney disease

Although nan insubstantial focuses connected MASH, Lipschutz's current trial is enrolling patients pinch diabetic kidney disease. However, fixed that nan incidence of MASH successful patients pinch diabetic nephropathy is complete 60%, this proceedings will besides let nan investigators to find nan effect of formoterol connected MASH, arsenic some conditions stem from nan aforesaid underlying metabolic dysfunction and are among nan astir communal and life-threatening complications of diabetes. 

"So it is simply a two-for-one study," he said.

Existing information successful some diseases offered encouragement for moving forward: "In some cases, location were quality retrospective information suggesting that this could beryllium working."

What comes next 

Several important questions stay earlier formoterol tin beryllium considered a curen for MASH aliases diabetic kidney disease. The caller liver findings are based mostly connected rodent models, and nan quality information is observational, showing associations alternatively than causation.

"Not everything that useful successful mice useful successful humans," Lipschutz pointed out.

Researchers besides still request to find applicable questions, including what would beryllium astir effective dose for metabolic disease, whether inhaled transportation will beryllium capable to impact nan liver aliases kidneys successful humans and really durable immoderate benefits mightiness beryllium complete time.

"No supplier is wholly safe. I ever opportunity to my patients, 'Anything beardown capable to do bully tin do bad,'" said Lipschutz.

The objective proceedings Lipschutz and his squad are presently enrolling for is designed to commencement answering these questions. If that proceedings yields encouraging results, it could pave nan measurement for a caller curen successful some diabetic kidney illness and MASH.

"If you could beryllium treating them pinch a repurposed, comparatively safe, inexpensive supplier that could beryllium a really bully thing," he added.

For now, nan activity highlights nan anticipation that a decades-old asthma medicine whitethorn person untapped imaginable arsenic a metabolic therapy, illustrating really sometimes investigation successful 1 area tin unfastened doors successful another.